EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease

Renae K Barr, Bryce W Barber, Jessica R Tait, Cornelia B Landersdorfer, Sam Salman, Gabrielle C Musk, Madhu Page-Sharp, Kevin T Batty, Joseph Kado, Laurens Manning, Jonathan R Carapetis, Ben J Boyd

European Journal of Pharmaceutics and Biopharmaceutics · 2023

DOI: 10.1016/j.ejpb.2023.06.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Renae K Barr und 11 weiteren Autor:innen. Beteiligte Einrichtung: Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia. Hauptthemen laut MEDLINE: Rheumatic Heart Disease, Rheumatic Fever. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Regular intramuscular (i.m.) benzathine penicillin G (BPG) injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. Patient adherence to IM BPG is poor, largely due to pain, the need for regular injections every 3-4 weeks and health sector delivery challenges in resource-limited settings. There is an urgent need for new approaches for secondary prophylaxis, such as an implant which could provide sustained penicillin concentrations for more than 6 months. METHODS: In this study we developed and evaluated a slow release implant with potential for substantially extended treatment. The side wall of a solid drug rich core was coated with polycaprolactone which acts as an impermeable barrier. The exposed surfaces at the ends of the implant defined the release surface area, and the in vitro release rate of drug was proportional to the exposed surface area across implants of differing diameter. The in vivo pharmacokinetics and tolerability of the implants were evaluated in a sheep model over 9 weeks after subcutaneous implantation. RESULTS: The absolute release rates obtained for the poorly water-soluble benzathine salt were dependent on the exposed surface area demonstrating the impermeability of the wall of the implant. The implants were well-tolerated after subcutaneous implantation in a sheep model, without adverse effects at the implantation site. Gross structural integrity was maintained over the course of the study, with erosion limited to the dual-exposed ends. Steady release of penicillin G was observed over the 9 weeks and resulted in approximately constant plasma concentrations close to accepted target concentrations. CONCLUSION: In principle, a long acting BPG implant is feasible as an alternative to i.m. injections for secondary prophylaxis of RHD. However, large implant size is currently a significant impediment to clinical utility and acceptability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rheumatic Heart DiseaseRheumatic FeverAnimalsSheepPenicillin G BenzathineAnti-Bacterial AgentsDelayed-Action PreparationsInjections, Intramuscular

Stichwörter der Autor:innen

Benzathine penicillin GDissolution, in vivo releasePolycaprolactoneRheumatic heart diseaseSecondary prophylaxis, long acting implant

Substanzen

Penicillin G BenzathineAnti-Bacterial AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia.
  • Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia.
  • Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia; Clinical Pharmacology and Toxicology Unit, PathWest Laboratory Medicine, Nedlands, WA, Australia; Medical School,…
  • Animal Care Services, University of Western Australia, Crawley, WA, Australia.
  • Curtin Medical School, Curtin University, Bentley, WA, Australia.
  • Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia; Medical School, University of Western Australia, Crawley, WA, Australia; Department of Infectious Diseases, Fiona…

Zitieren

APA

Barr, R. K., Barber, B. W., Tait, J. R., Landersdorfer, C. B., Salman, S., Musk, G. C., Page-Sharp, M., Batty, K. T., Kado, J., Manning, L., Carapetis, J. R., & Boyd, B. J. (2023). Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.06.006

Vancouver

Barr RK, Barber BW, Tait JR, Landersdorfer CB, Salman S, Musk GC, et al. Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.06.006

BibTeX
@article{Barr2023,
  author = {Barr, Renae K and Barber, Bryce W and Tait, Jessica R and Landersdorfer, Cornelia B and Salman, Sam and Musk, Gabrielle C and Page-Sharp, Madhu and Batty, Kevin T and Kado, Joseph and Manning, Laurens and Carapetis, Jonathan R and Boyd, Ben J},
  title = {Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2023},
  doi = {10.1016/j.ejpb.2023.06.006}
}
Kostenlos starten →